Nutex Health (NASDAQ:NUTX – Get Free Report) is expected to be issuing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of $4.95 per share and revenue of $215.0310 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 10:30 AM ET.
Nutex Health (NASDAQ:NUTX – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $6.52 EPS for the quarter, beating analysts’ consensus estimates of $3.99 by $2.53. The business had revenue of $216.49 million during the quarter, compared to analyst estimates of $227.80 million. Nutex Health had a net margin of 10.95% and a return on equity of 23.50%. On average, analysts expect Nutex Health to post $23 EPS for the current fiscal year and $24 EPS for the next fiscal year.
Nutex Health Stock Down 6.6%
NUTX stock opened at $157.21 on Thursday. The firm has a market capitalization of $1.08 billion, a PE ratio of 12.15 and a beta of 0.21. The company has a quick ratio of 3.12, a current ratio of 3.14 and a debt-to-equity ratio of 0.66. Nutex Health has a twelve month low of $77.21 and a twelve month high of $204.00. The stock’s 50 day moving average is $150.63 and its 200-day moving average is $130.51.
Institutional Trading of Nutex Health
Analyst Upgrades and Downgrades
Several analysts have commented on the stock. Zacks Research upgraded shares of Nutex Health to a “hold” rating in a research note on Monday, June 29th. Lake Street Capital initiated coverage on Nutex Health in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $235.00 target price for the company. Weiss Ratings lowered Nutex Health from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, July 10th. Wall Street Zen cut Nutex Health from a “strong-buy” rating to a “buy” rating in a research report on Monday. Finally, B. Riley Financial assumed coverage on Nutex Health in a research note on Friday, June 26th. They set a “buy” rating and a $290.00 price target for the company. Three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $243.33.
View Our Latest Report on Nutex Health
Nutex Health Company Profile
Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.
The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.
Featured Articles
- Five stocks we like better than Nutex Health
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Nutex Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutex Health and related companies with MarketBeat.com's FREE daily email newsletter.
